Small-molecule modulators of the NF-kappaB pathway newly identified by a translocation-based cellular assay

Area of Science:

• Molecular Biology
• Biochemistry
• Pharmacology

Background:

• Nuclear factor kappa B (NF-kappaB) is a key transcription factor implicated in numerous diseases, including cancer and inflammatory conditions.
• Dysregulation of the NF-kappaB pathway is a common hallmark of these major ailments, driving significant interest in therapeutic interventions.
• Existing reviews cover progress in NF-kappaB modulator development, highlighting the need for novel agents.

Purpose of the Study:

• To review and discuss newly discovered small molecule inhibitors and activators of the NF-kappaB pathway.
• To highlight novel regulators identified through high-throughput screening (HTS) within the NIH Molecular Libraries Screening Center Network (MLSCN).
• To present findings from Columbia's Molecular Libraries Screening Center (MLSC) utilizing a robust cellular assay.

Main Methods:

• Utilized high-throughput screening (HTS) to identify novel small molecules.
• Employed a well-designed and stable cellular assay for screening NF-kappaB pathway modulators.
• Leveraged resources from the NIH Roadmap for Medical Research's MLSCN.

Main Results:

• Identified a variety of structurally and functionally novel small molecules targeting the NF-kappaB pathway.
• Added new potential NF-kappaB regulators to the existing list of therapeutic agents.
• Confirmed the efficacy of the cellular assay for discovering pathway modulators.

Conclusions:

• The discovery of novel NF-kappaB modulators through HTS presents promising therapeutic avenues.
• These new agents expand the toolkit for targeting diseases associated with NF-kappaB dysregulation.
• Continued research into these novel molecules could lead to effective treatments for cancer and inflammatory diseases.